Literature DB >> 12070152

Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.

Isabelle Bernard-Pierrot1, Jean Delbé, Vincent Rouet, Marc Vigny, Marie-Emmanuelle Kerros, Danièle Caruelle, Daniel Raulais, Denis Barritault, José Courty, Pierre Emmanuel Milhiet.   

Abstract

Heparin affin regulatory peptide (HARP) is an heparin-binding growth factor, highly expressed in several primary human tumors and considered as a rate-limiting angiogenic factor in tumor growth, invasion, and metastasis. Implication of this protein in carcinogenesis is linked to its mitogenic, angiogenic, and transforming activities. Recently, we have demonstrated that the C-terminal residues 111-136 of HARP are required for its mitogenic and transforming activities (Bernard-Pierrot, I., Delbe, J., Caruelle, D., Barritault, D., Courty, J., and Milhiet, P. E. (2001) J. Biol. Chem. 276, 12228-12234). In this paper, HARP deleted of its last 26 amino acids was shown to act as a dominant negative effector for its mitogenic, angiogenic, transforming, and tumor-formation activities by heterodimerizing with the wild type protein. Similarly, the synthetic corresponding peptide P111-136 displayed in vitro inhibition of wild type HARP activities, but in this case, the inhibition was mainly explained by the competition of the peptide with HARP for the binding to the extracellular domain of the high affinity ALK receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070152     DOI: 10.1074/jbc.M202747200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.

Authors:  Weiwen Wang; Michelle E LeBlanc; Xiuping Chen; Ping Chen; Yanli Ji; Megan Brewer; Hong Tian; Samantha R Spring; Keith A Webster; Wei Li
Journal:  Angiogenesis       Date:  2017-04-26       Impact factor: 9.596

2.  A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPβ/ζ.

Authors:  Zoi Diamantopoulou; Oya Bermek; Apostolos Polykratis; Yamina Hamma-Kourbali; Jean Delbé; José Courty; Panagiotis Katsoris
Journal:  Mol Cancer       Date:  2010-08-25       Impact factor: 27.401

Review 3.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

4.  Upregulation of HARP during in vitro myogenesis and rat soleus muscle regeneration.

Authors:  Danièle Caruelle; Zohra Mazouzi; Irene Husmann; Jean Delbé; Arlette Duchesnay; Jean Gautron; Isabelle Martelly; José Courty
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

5.  The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells.

Authors:  Yamina Hamma-Kourbali; Oya Bermek; Isabelle Bernard-Pierrot; Racha Karaky; Dominique Martel-Renoir; Sophie Frechault; José Courty; Jean Delbé
Journal:  BMC Cancer       Date:  2011-05-30       Impact factor: 4.430

6.  Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.

Authors:  Damien Destouches; Diala El Khoury; Yamina Hamma-Kourbali; Bernard Krust; Patricia Albanese; Panagiotis Katsoris; Gilles Guichard; Jean Paul Briand; José Courty; Ara G Hovanessian
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.